Update on targeted therapies for advanced non-small cell lung cancer: Durvalumab in context

Sneha Gullapalli; Jordi Remon; Lizza E.L. Hendriks; Gilberto Lopes

doi:10.2147/OTT.S259308

Update on targeted therapies for advanced non-small cell lung cancer: Durvalumab in context

Sneha Gullapalli, Jordi Remon, Lizza E.L. Hendriks, Gilberto Lopes

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Abstract

Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono-therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

Original language	English
Pages (from-to)	6885-6896
Number of pages	12
Journal	OncoTargets and Therapy
Volume	13
DOIs	https://doi.org/10.2147/OTT.S259308
Publication status	Published - 1 Jan 2020
Externally published	Yes

Keywords

Durvalumab
MYSTIC
Non-small cell lung cancer
PACIFIC
Rechallenge

Access to Document

10.2147/OTT.S259308

Cite this

@article{48aac233ae35449db2a28449a30d0133,

title = "Update on targeted therapies for advanced non-small cell lung cancer: Durvalumab in context",

abstract = "Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono-therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.",

keywords = "Durvalumab, MYSTIC, Non-small cell lung cancer, PACIFIC, Rechallenge",

author = "Sneha Gullapalli and Jordi Remon and Hendriks, {Lizza E.L.} and Gilberto Lopes",

note = "Publisher Copyright: {\textcopyright} 2020 Gullapalli et al.",

year = "2020",

month = jan,

day = "1",

doi = "10.2147/OTT.S259308",

language = "English",

volume = "13",

pages = "6885--6896",

journal = "OncoTargets and Therapy",

issn = "1178-6930",

}

TY - JOUR

T1 - Update on targeted therapies for advanced non-small cell lung cancer

T2 - Durvalumab in context

AU - Gullapalli, Sneha

AU - Remon, Jordi

AU - Hendriks, Lizza E.L.

AU - Lopes, Gilberto

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono-therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

AB - Immune checkpoint inhibitors (ICIs) have transformed the therapeutic strategy and prognosis of advanced non-small cell lung cancer (NSCLC) patients. Nowadays, ICIs as monotherapy or in combination with chemotherapy are the standard of care treatment in advanced NSCLC, and in stage III, durvalumab (a programmed death ligand 1 inhibitor) is the unique drug approved as consolidation treatment after chemo-radiotherapy. This article reviews the pharmacological properties, clinical activity and safety of durvalumab as mono-therapy or in combination with chemotherapy or other ICIs in the therapeutic strategy of NSCLC patients.

KW - Durvalumab

KW - MYSTIC

KW - Non-small cell lung cancer

KW - PACIFIC

KW - Rechallenge

UR - http://www.scopus.com/inward/record.url?scp=85087930145&partnerID=8YFLogxK

U2 - 10.2147/OTT.S259308

DO - 10.2147/OTT.S259308

M3 - Article

AN - SCOPUS:85087930145

SN - 1178-6930

VL - 13

SP - 6885

EP - 6896

JO - OncoTargets and Therapy

JF - OncoTargets and Therapy

ER -

Update on targeted therapies for advanced non-small cell lung cancer: Durvalumab in context

Abstract

Keywords

Access to Document

Other files and links

Cite this